Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.

Benzinga Newsdesk www.benzinga.com Negative 97.3%

Neg 97.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!